Building oligonucleotide therapeutics using non-natural chemistries

Current Opinion in Chemical Biology

Volumn 10, Issue 6, 2006, Pages 607-614

  Wilson, Charles ^a   Keefe, Anthony D ^a  

^a Archemix Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; APTAMER; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; DIURETIC AGENT; IMMUNOSTIMULATING AGENT; ISIS 113715; LOCKED NUCLEIC ACID; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; OLIGONUCLEOTIDE; PEGAPTANIB; PEPTIDE NUCLEIC ACID; SMALL INTERFERING RNA; SPIEGELMER; VACCINE;

ADJUVANT THERAPY; CANCER; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG STABILITY; DRUG TARGETING; HALF LIFE TIME; HUMAN; INFECTION; NONHUMAN; OBESITY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; ULCERATIVE COLITIS;

OLIGONUCLEOTIDES; RNA, SMALL INTERFERING;

EID: 33751430435     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2006.10.001     Document Type: Review

References (50)

1. Lai J.C., Tan W., Benimetskaya L., Miller P., Colombini M., and Stein C.A. A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc Natl Acad Sci USA 103 (2006) 7494-7499
2. Miner Jr. P.B., Wedel M.K., Xia S., and Baker B.F. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 23 (2006) 1403-1413
3. Yoo B.H., Bochkareva E., Bochkarev A., Mou T.C., and Gray D.M. 2′-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Res 32 (2004) 2008-2016
4. Chi K.N., Eisenhauer E., Fazli L., Jones E.C., Goldenberg S.L., Powers J., Tu D., and Gleave M.E. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005) 1287-1296. Clinical trial results with a 2′-MOE gapmer antisense oligonucleotide directed towards clusterin are reported. Treatment is well tolerated and shown to block expression of the targeted gene in prostate tumours.
5. Prakash T.P., Johnston J.F., Graham M.J., Condon T.P., and Manoharan M. 2′-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo. Nucleic Acids Res 32 (2004) 828-833
6. Fluiter K., Frieden M., Vreijling J., Rosenbohm C., De Wissel M.B., Christensen S.M., Koch T., Orum H., and Baas F. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. ChemBioChem 6 (2005) 1104-1109. Modified gapmer antisense constructs containing different types of LNA substitutions are shown to retain high functional activity and good serum stability. Enhanced uptake into certain tissues is observed with amino-LNA modifications.
7. Surono A., Van Khanh T., Takeshima Y., Wada H., Yagi M., Takagi M., Koizumi M., and Matsuo M. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of Duchene muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Hum Gene Ther 15 (2004) 749-757
8. Opalinska J.B., Kalota A., Gifford L.K., Lu P., Jen K.Y., Pradeepkumar P.I., Barman J., Kim T.K., Swider C.R., Chattopadhyaya J., and Gewirtz A.M. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules. Nucleic Acids Res 32 (2004) 5791-5799
9. Lee D.S., Jung K.E., Yoon C.H., Lim H., and Bae Y.S. Newly designed six-membered azasugar nucleotide-containing phosphorothioate oligonucleotides as potent human immunodeficiency virus type 1 inhibitors. Antimicrob Agents Chemother 49 (2005) 4110-4120
10. Fletcher S., Honeyman K., Fall A.M., Harding P.L., Johnsen R.D., and Wilton S.D. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8 (2006) 207-216
11. Arora V., Devi G.R., and Iversen P.L. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol 5 (2004) 431-439
12. Liu Y., Braasch D.A., Nulf C.J., and Corey D.R. Efficient and isoform-selective inhibition of cellular gene expression by peptide nucleic acids. Biochemistry 43 (2004) 1921-1927
13. Robaczewska M., Narayan R., Seigneres B., Schorr O., Thermet A., Podhajska A.J., Trepo C., Zoulim F., Nielsen P.E., and Cova L. Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA). J Hepatol 42 (2005) 180-187
14. Wickstrom E., Choob M., Urtishak K.A., Tian X., Sternheim N., Talbot S., Archdeacon J., Efimov V.A., and Farber S.A. Sequence specificity of alternating hydroyprolyl/phosphono peptide nucleic acids against zebrafish embryo mRNAs. J Drug Targe. 12 (2004) 363-372
15. Hochreiter A.E., Xiao H., Goldblatt E.M., Gryaznov S.M., Miller K.D., Badve S., Sledge G.W., and Herbert B.S. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 12 (2006) 3184-3192
16. Hall A.H., Wan J., Spesock A., Sergueeva Z., Shaw B.R., and Alexander K.A. High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res 34 (2006) 2773-2781
17. Prater C.E., and Miller P.S. 3′-methylphosphonate-modified oligo-2′-O-methylribonucleotides and their Tat peptide conjugates: uptake and stability in mouse fibroblasts in culture. Bioconjug Chem 15 (2004) 498-507
18. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., Guyer D.R., and VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816. Results from two concurrent clinical trials testing the effect of repeated intravitreal injection with a stabilized anti-VEGF aptamer in patients with age-related macular degeneration are reported. Significant reduction in the rate of vision loss is observed in patients receiving treatment.
19. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U., Adamis A.P., Cunningham Jr. E.T., Goldbaum M., Guyer D.R., Katz B., and Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 1508 e1-25. Benefits of treatment with Macugen (pegaptanib), a stabilized anti-VEGF aptamer, in patients with age-related macular degeneration are shown to continue into the second year of clinical trials.
20. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., Claesson-Welsh L., and Janjić N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273 (1998) 20556-20567
21. Chelliserrykattil J., and Ellington A.D. Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA. Nat Biotechnol 22 (2004) 1155-1160
22. Burmeister P.E., Lewis S.D., Silva R.F., Preiss J.R., Horwitz L.R., Pendergrast P.S., McCauley T.G., Kurz J.C., Epstein D.M., Wilson C., and Keefe A.D. Direct in vitro Selection of a 2′-O-Methyl Aptamer to VEGF. Chem Biol 12 (2005) 25-33. Modified transcription conditions are identified that enable SELEX to be performed using 2′-O-methyl modifications for all four nucleotides. Highly stabilized anti-VEGF aptamers are generated without the need for post-SELEX optimization.
23. Padilla R., and Sousa R. Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2′-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res 27 (1999) 1561-1563
24. Padilla R., and Sousa R.A. A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs. Nucleic Acids Res 30 (2002) e138
25. Kato Y., Minakawa N., Komatsu Y., Kamiya H., Ogawa N., Harashima H., and Matsuda A. New NTP analogs: the synthesis of 4′-thioUTP and 4′-thioCTP and their utility for SELEX. Nucleic Acids Res 33 (2005) 2942-2951. Methods for synthesizing nuclease-resistant ribopyrimidine analogues containing 4′-thioribose are reported. The modified nucleotides are shown to be compatible with SELEX by their ability to be both transcribed and reverse transcribed using standard polymerases. High affinity thrombin aptamers are isolated from libraries containing the thioU and thioC modifications.
26. Vaught J.D., Dewey T., and Eaton B.E. T7 RNA polymerase transcription with 5-position modified UTP derivatives. J Am Chem Soc 126 (2004) 11231-11237. An assortment of modified uridine analogues bearing functional group modifications are shown to be compatible for transcription by T7 RNA polymerase, paving the way for future SELEX experiments.
27. Kuwahara M., Hanawa K., Ohsawa K., Kitagata R., Ozaki H., and Sawai H. Direct PCR amplification of various modified DNAs having amino acids: convenient preparation of DNA libraries with high-potential activities for in vitro selection. Bioorg Med Chem 14 (2006) 2518-2526. Amino acid-derived side chains are linked to the 5-position of dUTP and shown to support DNA synthesis catalyzed by the KOD DNA polymerase. These results set the stage for future SELEX experiments.
28. Jager S., Rasched G., Kornreich-Leshem H., Engeser M., Thum O., and Famulok M. A versatile toolbox for variable DNA functionalization at high density. J Am Chem Soc 127 (2005) 15071-15082
29. Shearman L.P., Wang S.P., Helmling S., Stribling D.S., Mazur P., Ge L., Wang L., Klussmann S., Macintyre D.E., Howard A.D., and Strack A.M. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 147 (2006) 1517-1526
30. Denekas T., Troltzsch M., Vater A., Klussmann S., and Messlinger K. Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide. Br J Pharmacol 148 (2006) 536-543
31. Purschke W.G., Eulberg D., Buchner K., Vonhoff S., and Klussmann S. An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. Proc Natl Acad Sci USA 103 (2006) 5173-5178
32. Schmidt K.S., Borkowski S., Kurreck J., Stephens A.W., Bald R., Hecht M., Friebe M., Dinkelborg L., and Erdmann V.A. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res 32 (2004) 5757-5765
33. Crinelli R., Bianchi M., Gentilini L., Palma L., Sorensen M.D., Bryld T., Babu R.B., Arar K., Wengel J., and Magnani M. Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity. Nucleic Acids Res 32 (2004) 1874-1885
34. Timchenko M.A., Rybalkina E.Y., Lomakin A.Y., Evlakov K.I., Serdyuk I.N., and Ivanovskaya M.G. Modified DNA fragments specifically and irreversibly bind transcription factor NF-kappaB in lysates of human tumor cells. Biochemistry (Mosc) 71 (2006) 454-460
35. Somasunderam A., Ferguson M.R., Rojo D.R., Thiviyanathan V., Li X., O'Brien W.A., and Gorenstein D.G. Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase. Biochemistry 44 (2005) 10388-10395
36. Bassett S.E., Fennewald S.M., King D.J., Li X., Herzog N.K., Shope R., Aronson J.F., Luxon B.A., and Gorenstein D.G. Combinatorial selection and edited combinatorial selection of phosphorothioate aptamers targeting human nuclear factor-kappaB RelA/p50 and RelA/RelA. Biochemistry 43 (2004) 9105-9115
37. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., Cameron D.W., and Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24 (2004) 693-701
38. Meng Y., Carpentier A.F., Chen L., Boisserie G., Simon J.M., Mazeron J.J., and Delattre J.Y. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116 (2005) 992-997
39. Vollmer J., Weeratna R.D., Jurk M., Davis H.L., Schetter C., Wullner M., Wader T., Liu M., Kritzler A., and Krieg A.M. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. J Leukoc Biol 76 (2004) 585-593. Immunostimulation via TLR9 is explored in different transfected cell types. Of particular note, CpI motifs (in which inosine substitutes for guanosine) shows significant activity.
40. Kraynack B.A., and Baker B.F. Small interfering RNAs containing full 2′-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA 12 (2006) 163-176. Contradicting previous reports, the authors show that it is possible to generate fully 2′-O-methyl substituted siRNA sense constructs that retain functional activity.
41. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., Johnson J.M., Lim L., Karpilow J., Nichols K., Marshall W., Khvorova A., and Linsley P.S. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12 (2006) 1197-1205. 2′-O-methyl modifications at specific positions within an siRNA guide strand are shown to reduce silencing of partially complementary transcripts while not affecting perfectly matched targets. The results suggest ways in which chemical modifications can be used to limit the extent of off-target effects with siRNA.
42. Prakash T.P., Allerson C.R., Dande P., Vickers T.A., Sioufi N., Jarres R., Baker B.F., Swayze E.E., Griffey R.H., and Bhat B. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 48 (2005) 4247-4253. The sensitivity of siRNA modifications at the 2′-position are explored through a systematic study. By introducing 2′-fluoro, 2′-O-methyl, and 2′-MOE modifications at discrete positions within sense and antisense strands of an siRNA construct and then assessing their functional activity in Hela cells, structure-activity relationships to guide the design of stabilized siRNAs can be inferred.
43. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, Leake D, Marshall WS, Khvorova A: Off-target effects by siRNA can induce toxic phenotype RNA. 2006, 12:1188-1196. Appropriate chemical modifications are shown to prevent off-target effects on gene expression with siRNA constructs.
44. Allerson C.R., Sioufi N., Jarres R., Prakash T.P., Naik N., Berdeja A., Wanders L., Griffey R.H., Swayze E.E., and Bhat B.J. Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. Med Chem 48 (2005) 901-904
45. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004) 173-178. Chemically modified siRNAs targeting apo-B are shown to block target expression following systemic administration.
46. Hall A.H., Wan J., Shaughnessy E.E., Ramsay Shaw B., and Alexander K.A. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 32 (2004) 5991-6000
47. Hoshika S., Minakawa N., Kamiya H., Harashima H., and Matsuda A. RNA interference induced by siRNAs modified with 4′-thioribonucleosides in cultured mammalian cells. FEBS Lett 579 (2005) 3115-3118
48. Takei Y., Kadomatsu K., Yuasa K., Sato W., and Muramatsu T. Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int J Cancer 114 (2005) 490-497
49. Kocisova E., Praus P., Rosenberg I., Seksek O., Sureau F., Stepanek J., and Turpin P.Y. Intracellular uptake of modified oligonucleotide studied by two fluorescence techniques. Biopolymers 74 (2004) 110-114
50. McNamara II J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., and Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24 (2006) 1005-1015. Chimeric molecules containing an aptamer specific for PSMA fused to an siRNA construct targeting cell survival genes are prepared and tested. The presence of the PSMA aptamer specifically targets the siRNA for delivery and uptake by prostate tumour cells, leading to improved inhibition of tumour growth in xenograft models.